In continuation of the company's announcement dated 27 January 2006 concerning a planned share repurchase programme, and pursuant to Section 204.33 of the New York Stock Exchange Listed Company Manual, this is to report that Novo Nordisk A/S (NYSE: NVO) and its wholly-owned affiliates on 30 September 2006 owned 19,913,934 of its own B shares of DKK 2, corresponding to a total nominal value of DKK 39,827,868 or 5.91 % of the total share capital.
In the third quarter of 2006 a total of 5,908,957 B shares were repurchased by Novo Nordisk A/S, and 221,247 B shares were disposed of to employees who exercised options granted by Novo Nordisk.
Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 22,750 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.
For further information please contact:
|
Media: |
Investors: |
|
|
|
|
Outside North America: |
Outside North America: |
|
Elin K Hansen |
Mogens Thorsager Jensen |
|
Tel: (+45) 4442 3450 |
Tel: (+45) 4442 7945 |
|
|
|
|
|
Christian Qvist Frandsen |
|
|
Tel: (+45) 4443 5182 |
|
|
|
|
|
Hans Rommer |
|
|
Tel: (+45) 4442 4765 |
|
|
|
|
In North America: |
In North America: |
|
Susan T Jackson |
Mads Veggerby Lausten |
|
Tel: (+1) 609 919 7776 |
Tel: (+1) 609 919 7937 |
Stock Exchange Announcement no 32 / 2006